Sensitive Clinical Marker Defined for Ulcerative Colitis Evolution
|
By LabMedica International staff writers Posted on 20 Sep 2016 |
|
Image: The semi-quantitative Calprotectin 50 + 200 combo card test (Photo courtesy of CerTest Biotec).
The two main subtypes of inflammatory bowel diseases (IBD), Crohn’s disease (CD) and ulcerative colitis (UC) are characterized by episodes of inflammatory activity and remission and determination of disease activity remains challenging, with most clinical scores correlating poorly with the inflammatory state.
Treatment of IBD patients has recently shifted from controlling symptoms to promoting endoscopic mucosal healing or deep remission and treatment promoting mucosal healing can slow the progression of the disease. In this context, laboratory biomarkers have gained importance in evaluating and predicting the response to therapy.
Scientists at the University of Chile (Santiago, Chile) prospectively recruited 26 patients grouped according to an endoscopic score and therapy response. Colonoscopic biopsies were collected at baseline and six months or when patients showed clinical activity. The protocol was reinitiated in patients requiring rescue therapy. Blood and stool were collected at baseline, one, three, six and 12 months.
Serum and intestinal ST2 (Interleukin 1 receptor-like 1) concentrations, as well as serum interleukin -33 (IL-33) levels were measured using an enzyme-linked immunosorbent assay (ELISA) kit for human ST2 or IL-33 (DuoSet, R&D Systems, Minneapolis, MN, USA). The ST2 detection assay is stable over time, with a detection limit of 20 pg/mL, while the IL-33 detection assay is less stable over time, with a detection limit of 23.4 pg/mL. The supernatant from the fecal samples were processed for the rapid semi-quantitative test Calprotectin 50+200 (CerTest Biotec S.L., Zaragoza, Spain). Mucosal ST2 detection was performed by immunofluorescence and the images captured using an Olympus confocal laser scanning biological microscope FV10i (Olympus America Inc., Melville, NY, USA).
The team reported that follow-up was completed in 24 patients. The statistically significant median and range of soluble sST2 levels varied from 173.5 pg/mL (136.6–274.0) to 86.5 pg/mL (54.6–133.2) in responders and 336.3 pg/mL (211.0–403.2) to 385.3 pg/mL (283.4–517.3) in non-responders at baseline and six months respectively. Soluble sST2 levels correlated with Mayo clinical and endoscopic subscore, mucosal ST2 and fecal calprotectin (FC) and showed a trend similar to that of FC in responders. Non-responders revealed an increased ST2 content, restricted to the lamina propria’s cellular infiltrate.
The authors concluded that during the follow-up, serial ST2 measurements decreased in those patients with a reduced endoscopic index at six months, indicating a positive response to therapy. In those patients, FC levels were also significantly decreased in direct correlation to sST2 levels. The accuracy of sST2 in endoscopic detection of UC strongly suggests its usefulness in monitoring relapse and outcome, as well as in identifying patients likely to benefit from a particular treatment. The study was published on August 28, 2016, in the journal BMC Gastroenterology.
Related Links:
University of Chile
R&D Systems
CerTest Biotec
Olympus America
Treatment of IBD patients has recently shifted from controlling symptoms to promoting endoscopic mucosal healing or deep remission and treatment promoting mucosal healing can slow the progression of the disease. In this context, laboratory biomarkers have gained importance in evaluating and predicting the response to therapy.
Scientists at the University of Chile (Santiago, Chile) prospectively recruited 26 patients grouped according to an endoscopic score and therapy response. Colonoscopic biopsies were collected at baseline and six months or when patients showed clinical activity. The protocol was reinitiated in patients requiring rescue therapy. Blood and stool were collected at baseline, one, three, six and 12 months.
Serum and intestinal ST2 (Interleukin 1 receptor-like 1) concentrations, as well as serum interleukin -33 (IL-33) levels were measured using an enzyme-linked immunosorbent assay (ELISA) kit for human ST2 or IL-33 (DuoSet, R&D Systems, Minneapolis, MN, USA). The ST2 detection assay is stable over time, with a detection limit of 20 pg/mL, while the IL-33 detection assay is less stable over time, with a detection limit of 23.4 pg/mL. The supernatant from the fecal samples were processed for the rapid semi-quantitative test Calprotectin 50+200 (CerTest Biotec S.L., Zaragoza, Spain). Mucosal ST2 detection was performed by immunofluorescence and the images captured using an Olympus confocal laser scanning biological microscope FV10i (Olympus America Inc., Melville, NY, USA).
The team reported that follow-up was completed in 24 patients. The statistically significant median and range of soluble sST2 levels varied from 173.5 pg/mL (136.6–274.0) to 86.5 pg/mL (54.6–133.2) in responders and 336.3 pg/mL (211.0–403.2) to 385.3 pg/mL (283.4–517.3) in non-responders at baseline and six months respectively. Soluble sST2 levels correlated with Mayo clinical and endoscopic subscore, mucosal ST2 and fecal calprotectin (FC) and showed a trend similar to that of FC in responders. Non-responders revealed an increased ST2 content, restricted to the lamina propria’s cellular infiltrate.
The authors concluded that during the follow-up, serial ST2 measurements decreased in those patients with a reduced endoscopic index at six months, indicating a positive response to therapy. In those patients, FC levels were also significantly decreased in direct correlation to sST2 levels. The accuracy of sST2 in endoscopic detection of UC strongly suggests its usefulness in monitoring relapse and outcome, as well as in identifying patients likely to benefit from a particular treatment. The study was published on August 28, 2016, in the journal BMC Gastroenterology.
Related Links:
University of Chile
R&D Systems
CerTest Biotec
Olympus America
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Rapid Molecular Testing Device
FlashDetect Flash10
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Latest Immunology News
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
- Companion Diagnostic Test for CRC Patients Identifies Eligible Treatment Population
- Novel Tool Uses Deep Learning for Precision Cancer Therapy
Channels
Clinical Chemistry
view channel
Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
Multiple myeloma is an incurable cancer of the bone marrow, and while many patients now live for more than a decade after diagnosis, a significant proportion relapse much earlier with poor outcomes.... Read more
Compact Raman Imaging System Detects Subtle Tumor Signals
Accurate cancer diagnosis often depends on labor-intensive tissue staining and expert pathological review, which can delay results and limit access to rapid screening. These conventional methods also make... Read more
Molecular Diagnostics
view channel
Ultra-Sensitive Blood Biomarkers Enable Population-Scale Insights into Alzheimer’s Pathology
Accurately estimating how many people carry Alzheimer’s disease pathology has long been a challenge, as traditional methods rely on small, clinic-based samples rather than the general population.... Read more
Blood Test Could Predict Death Risk in World’s Most Common Inherited Heart Disease
Hypertrophic cardiomyopathy (HCM) is the world’s most common inherited heart condition and affects millions of people globally. While some patients live with few or no symptoms, others develop heart failure,... Read more
Hematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreMicrobiology
view channel
New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
Urinary tract infections affect around 152 million people every year, making them one of the most common bacterial infections worldwide. In routine medical practice, diagnosis often relies on rapid urine... Read more
Breakthroughs in Microbial Analysis to Enhance Disease Prediction
Microorganisms shape human health, ecosystems, and the planet’s climate, yet identifying them and understanding how they are related remains a major scientific challenge. Even with modern DNA sequencing,... Read more
Pathology
view channel
Genetics and AI Improve Diagnosis of Aortic Stenosis
Aortic stenosis is a progressive narrowing of the aortic valve that restricts blood flow from the heart and can be fatal if left untreated. There are currently no medical therapies that can prevent or... Read more
AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer
Head and neck cancers are among the most aggressive malignancies worldwide, with nearly 900,000 new cases diagnosed each year. Monitoring these cancers for recurrence or relapse typically relies on tissue... Read moreTechnology
view channel
Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
Detecting cancer early and tracking how it responds to treatment remains a major challenge, particularly when cancer cells are present in extremely low numbers in the bloodstream. Circulating tumor cells... Read more
AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
Colorectal cancer is one of the most common and deadly cancers worldwide, and accurately predicting patient survival remains a major clinical challenge. Traditional prognostic tools often rely on either... Read more
Industry
view channel
BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) has entered into a strategic collaboration with the Institute for Immunology and Immune Health (I3H, Philadelphia, PA, USA) at the University... Read more
